Medtronic To Acquire Contego Medical For $380 Mln

Medtronic (MDT) agreed to acquire Contego Medical for $380 million, expanding its carotid and peripheral vascular products. The deal includes Contego's Neuroguard and Excipio devices. Medtronic expects completion in Q3 FY2024, with minimal EPS dilution in FY2027-2028. Shares rose 0.62% to $103.50 in overnight trading.

Original reporting
Published Nov 16, 2026, 1:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MDT
Bullish
high confidence
Mentioned
$MDT
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The acquisition is expected to be minimally dilutive to earnings and may provide incremental growth in the carotid and peripheral vascular segments.

02

Market read

First‑report M&A news with a $380 M deal size; stock reacted positively in overnight trade.

03

What to watch

Potential regulatory review and post‑acquisition integration costs are not detailed.

Relevance 9/10Novelty 9/10Timing: overnight trading today

Background

Medtronic (MDT) disclosed a $380 million acquisition of privately held Contego Medical, adding the Neuroguard IEP Direct System and Excipio thrombectomy devices.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic announced a $380 million acquisition of Contego Medical, adding new vascular products and expected to be minimally dilutive.

Expected impact

likely modest upside as investors price in the strategic expansion

Evidence & confidence

First‑report M&A of significant size; market already nudged the stock up 0.62% in overnight trading.

Market effects

strengthens Medtronic's position in the vascular and neuro‑intervention market, potentially pressuring peers.

U.S. medical‑device sector may see slight uplift from the strategic acquisition.

Limited to Medtronic and its competitive set; no broad macro impact.

Counterpoint

Deal size is modest relative to Medtronic's scale; integration risk could weigh on the stock.

Key entities

  • Medtronic Plc

    US‑listed medical‑device maker acquiring Contego.

  • Contego Medical

    Privately held developer of vascular devices.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.